Article
Molecular pathology of lung cancer: key to personalized medicine.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Mar 2012
Cheng Liang, Alexander Riley E, Maclennan Gregory T, Cummings Oscar W, Montironi Rodolfo, Lopez-Beltran Antonio, Cramer Harvey M, Davidson Darrell D, Zhang Shaobo
Abstract excerpt
The majority of lung adenocarcinoma patients with epidermal growth factor receptor- (EGFR) mutated or EML4-ALK rearrangement-positive tumors are sensitive to tyrosine kinase inhibitors. Both primary and acquired resistance in a significant number of those patients to these therapies remains a major clinical problem. The specific molecular mechanisms associated with tyrosine kinase inhibitor resistance are not...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.